Neha Jaiswal

Employment

• Roswell Park Comprehensive Cancer Center HRI Scientist
  2025 - Present
• Roswell Park Comprehensive Cancer Center Department of Pharmacology and Therapeutics Research Associate
  2022 - Present
• Roswell Park Cancer Institute Research Associate
  2020 - 2022
• Roswell Park Cancer Institute Department of Cancer Genetics Research Affiliate
  2018 - 2020
• H.Lee Moffitt Cancer Center Post-Doctoral Researcher
  2015 - 2018

Education

• University of Delhi - South Campus Ph.D
  2009 - 2015
• Thapar University Masters in Science M.Sc
  2007 - 2009
• University of Delhi Bachelors in Science B.Sc
  2004 - 2007

Projects & Funding

Projects & funding information is unavailable.

Publications (44)

• Table S2 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
  2026 DOI: 10.1158/0008-5472.31345565
  +Save
• Figure S1 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
  2026 DOI: 10.1158/0008-5472.31345592
  +Save
• Figure S2 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
  2026 DOI: 10.1158/0008-5472.31345589
  +Save
• Figure S3 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
  2026 DOI: 10.1158/0008-5472.31345586
  +Save
• Figure S4 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
  2026 DOI: 10.1158/0008-5472.31345580
  +Save
• Figure S5 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
  2026 DOI: 10.1158/0008-5472.31345577
  +Save
• Figure S6 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
  2026 DOI: 10.1158/0008-5472.31345574
  +Save
• Figure S7 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
  2026 DOI: 10.1158/0008-5472.31345571
  +Save
• Table S1 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
  2026 DOI: 10.1158/0008-5472.31345568
  +Save
• Figure S1 from EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression
  2026 DOI: 10.1158/0008-5472.31370712
  +Save